After the original identification of canine parvovirus (CPV) type 2 (CPV-2) in 1978, new antigenic variants such as CPV-2a, CPV-2b and CPV-2c have become widespread in the most countries. In this study, the genetic analysis of canine parvovirus was investigated in a total of 13 CPV vaccines, which have been licensed in Korea since late 1980s, and a field isolate of CPV from a dog with CPV infection clinical symptom. The partial VP2 gene of CPV was amplified and sequenced from 13 vaccine strains and one field isolate. The results showed that of the 13 vaccine strains, 10 strains belong to the CPV-2, 2 strains to CPV-2b, the remaining and one isolate to CPV-2a type, respectively. Several mutations of amino acids were detected at residues of the critical region of the commercial vaccine strains. These data suggest that new type of vaccines containing CPV-2a or CPV-2b/2c type may be required for the better prevention of new CPV infection in dog population in Korea, because CPV-2 contained in most licensed vaccines has been replaced by antigenic variants designated CPV-2a or CPV-2b/c in the worldwide dog population.

A total of 128 faecal samples of dogs suspected for canine parvovirus infection were examined by Haemagglutination (HA) and Haemagglutination inhibition (HI) tests. The prevalence of canine parvovirus infection was 45.30% (58/128) and the age wise maximum (70.20%) prevalence was found in dogs upto 6 month. The breed wise maximum (56.90%) prevalence was in Non-descript dogs and sex wise prevalence revealed no significant difference in male (45.9%) and female (43.3%).